One of the changes is that the #differential #discount #rates are now set at 3% for costs and 1.5% for effects (assuming a 1.5% growth rate in the consumption value of health).

Interested in the new Dutch guidelines for economic evaluations in healthcare?

Amarens Geuzinge and colleagues describe how they take the societal perspective to the next level.

You can find the paper here:

www.valueinhealthjournal.com/article/S109...

Our paper “The role of budget impact in reimbursement decisions in The Netherlands: interviews with decision-makers and pharmaceutical industry representatives” with Vivian Reckers-Droog and Joost Enzing is now in press in the European Journal of Health Economics:

link.springer.com/article/10.1...

Our paper “The role of budget impact in reimbursement decisions in The Netherlands: interviews with decision-makers and pharmaceutical industry representatives” with Vivian Reckers-Droog and Joost Enzing is now in press in the European Journal of Health Economics:

link.springer.com/article/10.1...

The paper “Does timing matter? The role of health information shocks in measuring willingness to pay”, with Carolin Brinkmann, @snb.bsky.social, and @tomstargardt.bsky.social, is now in print at the European Journal of Health Economics and can be found here:

link.springer.com/article/10.1...

We are hiring! Two great PhD positions at the Health Economics department of the Erasmus School of Health Policy & Management!

@arthurattema.bsky.social